Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Farrell

Showing results (131-140 of 172) with videos related to

Pageof 18
Sort By:
Journal of Clinical Microbiology|September 14, 2012
Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumoniaRodrigo E Mendes, Lalitagauri M Deshpande, Davida S Smyth, et al.
Diagnostic Microbiology and Infectious Disease|February 25, 2015
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013Helio S Sader, David J Farrell, Rodrigo E Mendes, et al.
Emerging Infectious Diseases|June 21, 2005
Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistanceDavid J Farrell, Stephen G Jenkins, Steven D Brown, et al.
International Journal of Antimicrobial Agents|May 17, 2005
Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia modelPrachi K Dandekar, Peter Williams, Pamela R Tessier, et al.
Antimicrobial Agents and Chemotherapy|May 29, 2014
Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agentsRodrigo E Mendes, Donald Biek, Ian A Critchley, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2016
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014Michael D Huband, Mariana Castanheira, Robert K Flamm, et al.
The Journal of Antimicrobial Chemotherapy|October 10, 2015
Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13)Rodrigo E Mendes, Mariana Castanheira, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy|April 8, 2015
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, et al.
The New England Journal of Medicine|April 14, 2006
The effect of telithromycin in acute exacerbations of asthmaSebastian L Johnston, Francesco Blasi, Peter N Black, et al.
Journal of Global Antimicrobial Resistance|December 13, 2016
Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agentsRodrigo E Mendes, Mariana Castanheira, David J Farrell, et al.
Pageof 18

Showing results (131-140 of 172) with videos related to

Sort By:
Pageof 18
Journal of Clinical Microbiology|September 14, 2012
Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumoniaRodrigo E Mendes, Lalitagauri M Deshpande, Davida S Smyth, et al.
Diagnostic Microbiology and Infectious Disease|February 25, 2015
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013Helio S Sader, David J Farrell, Rodrigo E Mendes, et al.
Emerging Infectious Diseases|June 21, 2005
Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistanceDavid J Farrell, Stephen G Jenkins, Steven D Brown, et al.
International Journal of Antimicrobial Agents|May 17, 2005
Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia modelPrachi K Dandekar, Peter Williams, Pamela R Tessier, et al.
Antimicrobial Agents and Chemotherapy|May 29, 2014
Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agentsRodrigo E Mendes, Donald Biek, Ian A Critchley, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2016
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014Michael D Huband, Mariana Castanheira, Robert K Flamm, et al.
The Journal of Antimicrobial Chemotherapy|October 10, 2015
Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13)Rodrigo E Mendes, Mariana Castanheira, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy|April 8, 2015
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, et al.
The New England Journal of Medicine|April 14, 2006
The effect of telithromycin in acute exacerbations of asthmaSebastian L Johnston, Francesco Blasi, Peter N Black, et al.
Journal of Global Antimicrobial Resistance|December 13, 2016
Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agentsRodrigo E Mendes, Mariana Castanheira, David J Farrell, et al.
Pageof 18